omniture

CPHI to Present at the Global Hunter Securities China Conference in San Francisco on July 11 - 13, 2010

2010-07-06 14:16 1156

HAIKOU CITY, China, July 6 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. (NYSE AMEX: CPHI) ("China Pharma" or the "Company"), a leading fully-integrated specialty pharmaceutical company in China, today announced that the Company's Chief Financial Officer, Mr. Frank Waung, has been invited by Global Hunter Securities to present at the Global Hunter Securities ("GHS") China Conference.

The GHS China Conference will be held on July 11 - 13, 2010 at the St. Regis Hotel in San Francisco. Mr. Frank Waung is scheduled to make a presentation at 3 P.M. PT on Monday, July 12, 2010 and will be available to meet with investors throughout the conference.

For further details, please contact your respective institutional sales representative.

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a rapidly growing specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high margin business model is driven by market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across 30 provinces, municipalities and autonomous regions. The Company's wholly owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as success of new product development, unanticipated changes in product demand, increased competition, downturns in the Chinese economy, uncompetitive levels of research and development, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

For more information, please contact:

China Pharma Holdings, Inc.

Tel: +86-898-6681-1730 (China)

Email: hps@chinapharmaholdings.com

CCG Investor Relations

Vivian Chen, Sr. Market Intelligence Exec.

Tel: +1-646-701-7445 (New York)

Email: vivian.chen@ccgir.com

Source: China Pharma Holdings, Inc.
Related Stocks:
AMEX:CPHI
collection